A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2012-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/annrheumdis-2011-200704PMID 22328739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of the Acute Phase Response by Cytokines

  2015cited by this paper
• Newer Biological Agents in Rheumatoid Arthritis

  2012cited by this paper
• IL‐6: Regulator of Treg/Th17 balance

  2010cited by this paper
• Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007.

  2010cited by this paper
• The impact of rheumatoid arthritis and treatment on patients' lives.

  2010cited by this paper
• ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.

  2010cited by this paper
• Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics.

  2010cited by this paper
• Treating rheumatoid arthritis to target: recommendations of an international task force

  2010cited by this paper
• Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor

  2009cited by this paper
• Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial

  2009cited by this paper
• Use of “spydergrams” to present and interpret SF-36 health-related quality of life data across rheumatic diseases

  2009cited by this paper
• Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

  2008cited by this paper
• Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.

  2008cited by this paper
• Interleukin-6 in the pathogenesis of rheumatoid arthritis.

  2007cited by this paper
• Interleukin 6: from bench to bedside

  2006cited by this paper
• The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

  2006cited by this paper
• Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

  2006cited by this paper
• Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis

  2006cited by this paper
• Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane

  2006cited by this paper
• Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002

  2006cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

  2005cited by this paper
• Mechanisms of Disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis

  2005cited by this paper
• Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.

  2004cited by this paper
• The Relative Contribution of Domains of Quality of Life to Overall Quality of Life for Different Chronic Diseases

  2004cited by this paper
• Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

  2004cited by this paper
• Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

  2004cited by this paper
• Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

  2004cited by this paper
• IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation.

  2003cited by this paper
• Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.

  2003cited by this paper
• Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice.

  2002cited by this paper
• Prevalence of disabilities and associated health conditions among adults--United States, 1999.

  2001cited by this paper
• Drug-induced liver disease.

  2000cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• The Pathophysiologic Roles of Interleukin-6 in Human Disease

  1998cited by this paper
• Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

  1996cited by this paper
• Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.

  1995cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis.

  1995cited by this paper
• High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo

  1992cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• The MOS 36-Item Short-Form Health Survey (SF-36)

  1992cited by this paper
• IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.

  1988cited by this paper
• B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes

  1988cited by this paper
• The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

  1988cited by this paper
• Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

  1985cited by this paper
• Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver

  1978cited by this paper
• Extended Report

  year unknowncited by this paper
• Research Paper Mediators of Inflammation, 7, 347–353 (1998)

  year unknowncited by this paper

• The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

  2026cites this paper
• Navigating IL-6: From molecular mechanisms to therapeutic breakthroughs.

  2024cites this paper
• Escherichia coli and Pichia pastoris: microbial cell-factory platform for full-length IgG production

  2024cites this paper
• The role of inflammation in autoimmune disease: a therapeutic target

  2023cites this paper
• Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?

  2023cites this paper
• Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials

  2023cites this paper
• Rheumatoid arthritis: current therapeutics compendium

  2022cites this paper
• The use of fungi for the production of biotechnological products in the field of health

  2022cites this paper
• Current Knowledge of Biologics in Treatment of Noninfectious Uveitis

  2022cites this paper
• Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies

  2022cites this paper
• Restriction of interleukin‐6 alters endothelial cell immunogenicity in an allogenic environment

  2022cites this paper
• A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

  2022cites this paper
• Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases

  2022cites this paper
• Restriction of interleukin‐6 alters endothelial cell immunogenicity in an allogenic environment

  2022cites this paper
• Impacto del tratamiento con metotrexate en la funcionalidad de pacientes con Artritis Reumatoide

  2022cites this paper
• Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology

  2020cites this paper
• Treatment of juvenile idiopathic arthritis: what's new?

  2019cites this paper
• Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial

  2019cites this paper
• Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials

  2019cites this paper
• Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials

  2018cites this paper
• Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?

  2018cites this paper
• The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer.

  2018cites this paper
• Current and future perspectives in the management of juvenile idiopathic arthritis.

  2018cites this paper
• Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018

  2018cites this paper
• Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis

  2018cites this paper
• Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients

  2018cites this paper
• Biological Therapies that Target Inflammatory Cytokines to Treat Uveitis

  2018cites this paper
• Interleukin-6: designing specific therapeutics for a complex cytokine

  2018cites this paper
• Current and Emerging Treatments for Psoriatic Arthritis

  2018cites this paper
• A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study

  2017cites this paper
• Selected cytokine pathways in rheumatoid arthritis

  2017cites this paper
• The growth factor midkine may play a pathophysiological role in rheumatoid arthritis

  2017cites this paper
• IL-6 blockers in systemic onset juvenile idiopathic arthritis.

  2016cites this paper
• Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases

  2016cites this paper
• The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

  2016cites this paper
• Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer

  2016cites this paper
• Optimizing biological treatments for rheumatoid arthritis

  2016cites this paper
• Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial

  2016cites this paper
• Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys

  2016cites this paper
• Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options

  2016cites this paper
• New therapeutic approaches in rheumatoid arthritis.

  2016cites this paper
• Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial

  2016cites this paper
• Biologic Therapy of Psoriatic Arthritis

  2016cites this paper
• IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future

  2015cites this paper
• Biologicals in rheumatoid arthritis: current and future

  2015cites this paper
• Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions

  2015cites this paper
• Novel treatment options for juvenile idiopathic arthritis

  2015cites this paper
• From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis

  2015cites this paper
• Rheumatoid arthritis: IL-6 inhibition in RA—déjà vu all over again?

  2015cites this paper
• A short history of biological therapy for psoriatic arthritis.

  2015cites this paper
• ADVANCES IN THERAPIES FOR RHEUMATOID ARTHRITIS

  2015cites this paper
• The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study

  2015influential citation
• Biologic Therapy for Psoriatic Arthritis.

  2015cites this paper
• Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.

  2015cites this paper
• IL-17RA in Intestinal Inflammation: Structure, Signaling, Function, and Clinical Application

  2015cites this paper
• Targeting interleukin-6 for noninfectious uveitis

  2015cites this paper
• Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

  2015cites this paper
• Advanced analyses of kinetic stabilities of iggs modified by mutations and glycosylation

  2015cites this paper
• Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside—a Comprehensive Review

  2015cites this paper
• Biopharmaceutical discovery and production in yeast.

  2014cites this paper
• Impact of biological therapy on spondyloarthritis

  2014cites this paper
• Diagnosing and treating psoriatic arthritis: an update

  2014cites this paper
• Therapy of inflammatory bowel disease: what to expect in the next decade

  2014cites this paper
• Discovery and characterization of olokizumab

  2014cites this paper
• Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics.

  2014cites this paper
• Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.

  2014cites this paper
• Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis

  2014cites this paper
• Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

  2014cites this paper
• Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

  2014cites this paper
• JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis

  2014cites this paper
• Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs

  2014influential citation
• IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab

  2014cites this paper
• Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.

  2014cites this paper
• Targeting of Interleukin-6 for the Treatment of Rheumatoid Arthritis: A Review and Update

  2014cites this paper
• Investigational drugs for treating psoriatic arthritis

  2014cites this paper
• IL-6 blockade in chronic inflammatory diseases

  2014cites this paper
• MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders

  2014cites this paper
• Psoriatic arthritis and spondyloarthritis assessment and management update

  2013cites this paper
• Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis

  2013influential citation
• Targeting Interleukin-6 in Rheumatoid Arthritis

  2013cites this paper
• With or Without Sugar? (A)glycosylation of Therapeutic Antibodies

  2013cites this paper
• Monoclonal antibody treatments for rheumatoid arthritis

  2013influential citation
• Response to M. Boers' concerns about spydergrams.

  2013cites this paper
• Tocilizumab in Pediatric Rheumatology: The Clinical Experience

  2013cites this paper
• Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.

  2013cites this paper
• Translational research in rheumatoid arthritis : exploiting melanocortin receptors

  2013cites this paper
• Monoclonal antibodies in rheumatoid arthritis

  2013cites this paper
• antirheumatic drugs: 2013 update synthetic and biological disease-modifying management of rheumatoid arthritis with EULAR recommendations for the

  2013cites this paper
• IL-17 in the Rheumatologist's Line of Sight

  2013cites this paper
• The problem of choice: current biologic agents and future prospects in RA

  2013cites this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

  2013cites this paper
• IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.

  2012influential citation
• Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

  2012cites this paper
• Consensus Statement

  2004cites this paper
• Article Reference

  year unknowncites this paper